 SELLAS Life Sciences Group Inc NASDAQ: SLS announced updated data from a Phase 1 clinical trial of galinpepimut-S GPS, combined with Bristol-Myers Squibb Cos NYSE: BMY nivolumab Opdivo in with malignant pleural mesothelioma MPM. The trial included patients. 